Oct262023

Sodium-Glucose Cotransporter 2 Inhibitor Effects on Heart Failure Hospitalization and Cardiac Function: Systematic Review

Recent Publications

This paper, co-authored by Associate Professor Roy Rasalam (Principal Investigator at AusTrials Sunshine in Melbourne), systematically reviews randomized controlled trials assessing effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) on hospitalization for heart failure (HHF) and cardiac structure/function and explore randomized controlled trial (RCT)-derived evidence for SGLT2i efficacy mechanisms in heart failure (HF). This review found…

Read article
Oct142022

Meaningful Relief with Flurbiprofen 8.75 mg Spray in Patients with Sore Throat Due to Upper Respiratory Tract Infection

Recent Publications

This paper presents the result from a randomised, double-blind study in adults with sore throat due to upper respiratory tract infection who took flurbiprofen (n = 249) or placebo spray (n = 256). Pain relief was assessed using the Sore Throat Relief Rating Scale.  In this study, flurbiprofen spray provided significantly greater relief versus placebo…

Read article
Oct142022

Efficacy of the Adjuvanted Recombinant Zoster Vaccine (RZV) by Sex, Geographic Region, and Geographic Ancestry/Ethnicity: A Post-Hoc Analysis of the ZOE-50 and ZOE-70 Randomised Trials

Recent Publications

Herpes zoster (HZ) risk appears to vary by sex and geographic ancestry/ethnicity. In 2 randomised clinical trials, participants received 2 doses of adjuvanted recombinant zoster vaccine (RZV) or placebo intramuscularly, 2 months apart. In this post-hoc analysis, the efficacy of RZV against HZ and postherpetic neuralgia (PHN) were investigated by sex, geographic region, and geographic…

Read article
Oct142022

Safety Profile of the Adjuvanted Recombinant Zoster Vaccine: Pooled Analysis of Two Large Randomised Phase 3 Trials

Recent Publications

The ZOE-50 and ZOE-70 phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. This article presents a comprehensive overview of the safety data from these studies. Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses…

Read article